Google+ Facebook Twitter Twitter

CRISPR treatment for blood diseases

A collaborative team of researchers has presented preliminary data showing that a CRISPR-based gene-editing therapy for inherited blood disorders is safe and effective.

The one-time gene editing treatment, known as CTX001, which was discovered and developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has been given to 22 patients – 15 with transfusion-dependent beta-thalassaemia and seven with sickle cell disease – with the aim of boosting the production of fetal haemoglobin in order to correct the defective gene for haemoglobin associated with both diseases.

All the patients demonstrated sustained increases in fetal haemoglobin and total haemoglobin, with limited and manageable side effects related to the transplant procedure.

The patients with beta-thalassaemia have been transfusion-free since they received the infusion.

The seven patients with severe sickle cell disease have had no vaso-occlusive crises – the acute episodes of severe pain that also involve organ damage.

Stephan Grupp, study co-author and pioneer of the first cellular immunotherapy in childhood cancer, said: “What we’re seeing in these early days is how transformational this is for the sickle cell patients we’ve seen. We are hearing that it is life-changing.”

Image credit | iStock

Related Articles

IBMS research grants 2021

The five recipients of the IBMS research grants in 2021 introduce us to their research projectsnand discuss what impact their work could have.

Tech news: December

This month's top tech news stories

Blood marker for peripheral artery disease

Researchers at Washington University School of Medicine have shown that high levels of a specific protein circulating in the blood are an accurate marker for a severe type of peripheral artery disease that narrows the arteries in the legs and can raise the risk of heart attack.

Under the microscope: HeLa cells

In November's Under the Microscope, we focus on the HeLa cell line.